GlassScriptPhysician profile
Kathy Keimig
NPI 1760564801
$20,102.22
in general payments reported to CMS, 2019-2025
37 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $1,292 · 2021: $1,492 · 2022: $1,528 · 2023: $5,485 · 2024: $6,786 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,575 · Food and Beverage: $5,001 · Travel and Lodging: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,575.00 |
| Food and Beverage | $5,001.08 |
| Travel and Lodging | $523.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,006.40 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $1,570.30 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,445.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,169.88 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,073.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $747.63 | 2019-2020 | |
| Pfizer INC. | $706.15 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $494.93 | 2019-2024 | Trintellix, Glassia |
| Janssen Pharmaceuticals, INC | $475.98 | 2022-2025 | Spravato |
| Astellas Pharma US INC | $304.68 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $267.11 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $258.28 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.09 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $144.58 | 2019-2021 | |
| Axsome Therapeutics, INC. | $144.43 | 2024-2025 | Auvelity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Keimig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.